A single-dose vial of 2 ml contains amikacin sulfate, base 100 mg equivalent IP. Other ingredients such as methylparaben I.P. and propylparaben I.P.
Usage of this drug is indicated in the treatment of infections due to gram-negative organisms such as bacterial septicemia, neonatal infections, urinary tract infections, other infections of the respiratory tract, bone-related infections, joint structure-related infections, meningitis, post-operative infections, burns, intra-abdominal infections.
Mild to moderate side effects have been observed. Such as nausea, vomiting, the elevation of serum creatinine, albuminuria, skin rash, drug fever, headache, arthralgia, anemia, hypotension, and apnea in severe casesia.
This drug is to be prescribed cautiously in patients with renal dysfunction, and hepatic disorders.
This drug is contraindicated in patients with a history of diarrhea due to a Clostridium difficile infection, as it may worsen it; patients with a history of Parkinsonism; patients with myasthenia gravis; patients with dehydration; and patients with a history of hypocalcemia.
Dosage and administration
In adults, the usual dosage consists of 15 mg/kg per day in 2-3 divided doses, given by intramuscular injection or intravenous infusion over 30–60 minutes. 7.5 mg/kg over a 12-hour duration, and accordingly, should not exceed 15 mg per day.
(We have also established roots and begun this new venture in other countries as well, such as Kayman, Equador, the PLO, Oman, Turks and Caicos, and Somalia.)